Fiche du document
3 août 2021
- doi: 10.1080/21645515.2021.1891752
- issn: 2164-5515
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1080/21645515.2021.1891752
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33909542
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2164-554X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_448E1556B8F59
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Communicable diseases--Vaccination Preventive inoculation Inoculation Preventive inoculation Diseases--VaccinationCiter ce document
A. Bovay et al., « Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses. », Serveur académique Lausannois, ID : 10.1080/21645515.2021.1891752
Métriques
Partage / Export
Résumé
By preventing infectious diseases, vaccines contribute substantially to public health. Besides, they offer great opportunities to investigate human immune responses. This is particularly true for live-attenuated virus vaccines which cause resolving acute infections and induce robust immunity. The fact that one can precisely schedule the time-point of vaccination enables complete characterization of the immune response over time, short-term and over many years. The live-attenuated Yellow Fever virus vaccine strain YF-17D was developed in the 1930's and gave rise to the 17D-204 and 17DD vaccine sub-strains, administered to over 600 million individuals worldwide. YF vaccination causes a systemic viral infection, which induces neutralizing antibodies that last for a lifetime. It also induces a strong T cell response resembling the ones of acute infections, in contrast to most other vaccines. In spite of its use since 1937, learning how YF vaccination stimulates such strong and persistent immune responses has gained substantial knowledge only in the last decades. Here we summarize the current state of knowledge on the immune response to YF vaccination, and discuss its contribution as a human model to address complex questions on optimal immune responses.